华东医药：目前创新药研发中心正在推进90余项创新药管线项目

Core Insights - The company emphasizes innovation in drug development as its core strategy, with over 90 innovative drug pipeline projects currently in progress [1] - The focus of the company's R&D is on major disease areas such as endocrinology, oncology, and autoimmune diseases, with a forward-looking and differentiated advantage in target layout [1] - Despite intense industry competition, the company is at the forefront in terms of technical accumulation and clinical advancement speed in its niche areas, with several potential products expected to achieve milestone breakthroughs in the next 2-3 years [1] - The company plans to continuously enhance R&D conversion efficiency and accelerate the market launch of key products to reward investor trust with innovative results [1]